Coronavirus Notebook: EMA OKs More Vaccine Production Plants, WHO Sounds Alert Over Africa
Vaxzevria should not be given to people who have had capillary leak syndrome, the EU regulator says. The G7 leaders have made big pledges on vaccine donations, and international regulatory bodies have issued a guide to shoring up confidence in vaccination.
You may also be interested in...
Coronavirus Notebook: EU Industry Claims ‘Undeniable’ Role Of IP, UK Targets Younger At-Risk Groups For Vaccination
Draft EU legislation on tackling cross-border health threats has taken another step forward, as health authorities say the Delta variant of the SARS-CoV-2 virus will be the “globally dominant strain” over the coming months.
All four coronavirus vaccines authorized for marketing in the EU/European Economic Area have had their safety information updated because of various adverse events including myocarditis, pericarditis and capillary leak syndrome.
US FDA will rapidly update fact sheets with information on myocarditis/pericarditis occurring primarily in young men and adolescent males following the second dose, agency's Doran Fink tells the CDC’s Advisory Committee on Immunization Practices, which said benefit-risk of the Pfizer/BioNTech and Moderna vaccines remains favorable.